MGMT and glioma: In the TCGA cohort, glioma patients of the cluster 1 subgroup with the clinicopathological characteristics, age > 45 years, more malignant type of histology, higher WHO grade, IDH wild type, 1p19q codeletion non-codel, and MGMT promoter unmethylated showed significantly higher levels of risk score, while no differences were observed between patients satisfied by gender (Fig. 4B–I).